<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01155960</url>
  </required_header>
  <id_info>
    <org_study_id>BA0859094</org_study_id>
    <nct_id>NCT01155960</nct_id>
  </id_info>
  <brief_title>Bioavailability Study of Anastrozole Tablets 1 mg of Dr.Reddy's Under Fed Conditions</brief_title>
  <official_title>An Open Label, Balanced, Randomized,Two-Treatment, Two-Sequence, Two Period, Crossover, Single Dose Comparative Oral Bioavailability Study Of Anastrozole Tablets 1 mg (Test) Of Dr. Reddy's Laboratories Ltd., India And ARIMIDEX® Tablets 1 mg (Reference) Of Astrazeneca Pharmaceuticals LP, USA In Post Menopausal Healthy Women Subjects Under Fed Conditions.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Reddy's Laboratories Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. Reddy's Laboratories Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare bioavailability in healthy, post menopausal women
      subjects under fed conditions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Open label, balanced, randomized, two treatment, two-sequence, two periods, crossover, single
      dose, comparative oral bioavailability study in healthy, post menopausal women subjects under
      fed conditions.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bioavailability based on Cmax and AUC parameters</measure>
    <time_frame>3 Months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Arimidex</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arimidex® Tablets 1 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Anastrozole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Anastrozole Tablets 1 mg of Dr.Reddy's Laboratories Limited</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anastrozole</intervention_name>
    <description>Anastrozole Tablets 1 mg of Dr.Reddy's Laboratories Limited</description>
    <arm_group_label>Arimidex</arm_group_label>
    <arm_group_label>Anastrozole</arm_group_label>
    <other_name>Arimidex® Tablets 1 mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. The subjects should be postmenopausal healthy women who have attained complete
             menopause naturally or surgically and have not had menstruation for at least one year
             and are not on hormone replacement therapy.

          2. The subjects should have Estradiol level ≤ 20 pg/ml &amp; serum follicular stimulating
             hormone (FSH) level ≥ 50 mlU/ml during the screening.

          3. The subjects should be screened within 21 days prior to the administration of first
             dose of the study drug.

          4. The subjects should have a BMI between 18.5 to 26.4 (30-39 years), 18.5 to 27.8 (40-49
             years), 18.5 to 28.4 (50-59 years) &amp; 18.5 to 27.5 (60-69 years) weight in kg/ height2
             in meter.

          5. The subjects should be able to communicate effectively with study personnel.

          6. The subjects should be able to give written informed consent to participate in the
             study.

        Exclusion Criteria:

          1. The subjects who have a history of allergic responses to Anastrozole or other related
             drugs.

          2. The subjects who are using female hormone replacement therapies, thyroid hormone
             replacement therapies, or antihypertensive therapies.

          3. The subjects who have significant diseases or clinically significant abnormal findings
             during screening, (medical history, physical examination, laboratory evaluations, ECG,
             X-ray &amp; lower abdominal ultrasonography recordings).

          4. The subjects who have any disease or condition which might compromise the
             haemopoeitic, gastrointestinal, renal, hepatic, cardiovascular, respiratory, central
             nervous system, diabetes, psychosis or any other body system.

          5. The subjects who have a history or presence of bronchial asthma.

          6. The subject who have used of enzyme-modifying drugs within 30 days prior to receiving
             the first dose of study medication.

          7. The subjects who have history of drug dependence, recent history of alcoholism or of
             moderate alcohol use.

          8. The subjects who are smokers, who smoke more than or equal to 10 cigarettes per day or
             more than or equal to 20 biddies per day or those who cannot refrain from smoking
             during study period.

          9. The subjects with a history of difficulty with donating blood or difficulty in
             accessibility of veins.

         10. The subjects who have donated (1 unit: 350 ml / 450 ml) blood within 90 days prior to
             receiving the first dose of study medication.

         11. The subjects who have a positive hepatitis screen (includes subtypes A, B, C &amp; E).

         12. The subjects who have a positive test result for Human Immunodeficiency Virus (HIV)
             antibody and / or syphilis Rapid Plasma Reagin, Venereal Disease Research Laboratory
             (RPR/VDRL).

         13. The subject who received an investigational product, or has participated in a drug
             research study within a period of 90 days prior to the first dose of the study
             medication administration.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>37 Years</minimum_age>
    <maximum_age>67 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ronak Modi, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>BA Research India Ltd.,</affiliation>
  </overall_official>
  <verification_date>July 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 1, 2010</study_first_submitted>
  <study_first_submitted_qc>July 1, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 2, 2010</study_first_posted>
  <last_update_submitted>July 1, 2010</last_update_submitted>
  <last_update_submitted_qc>July 1, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 2, 2010</last_update_posted>
  <responsible_party>
    <name_title>Dr. Ramesh Mullangi -Director</name_title>
    <organization>Dr.Reddy's Laboratories Limited</organization>
  </responsible_party>
  <keyword>Bioavailability</keyword>
  <keyword>Anastrozole</keyword>
  <keyword>Crossover</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anastrozole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

